What We Do and Why It Matters

KineMed applies highly innovative techniques to the study of biological processes in living organisms, increasing the effectiveness of pharmaceutical Research & Development and enabling a greater flow of superior medicines for lower costs.

We help many pharmaceutical partners generate new medicines and are generating our own focused pipeline of potential best-in-class medicines.

We use stable isotopes to delve deeply into key biological processes in animals and man to rapidly generate crucial insights into health, disease, and drug actions. These insights can overcome two of the major challenges confronting the successful creation of new medicines:

  • Translation: (1) Effectively interpreting and applying pre-clinical observations to advance drugs in the clinic and (2) intelligently using clinical observations to work on the right drugs in the laboratory

    and

  • Personalization: Appropriately detecting and adapting to the heterogeneity of particular diseases or patients to get the right drugs into the appropriate patients at optimized doses to produce the best outcomes.

KineMed embodies a powerful, proprietary platform in Translational Medicine & Personalized Medicine integrated into pharmaceutical Research & Development, propelling the successful creation of best-in-class medicines.

Upcoming Events

January 13, 2010
Biotech Showcase 2010
Kinemed Presents Wednesday, January 13, 2010 at 3:00 PT
Learn More

Latest News RSS iconRecent Publications
2010-02-08
KineMed Broadens Collaboration with Bristol-Myers Squibb
2009-11-19
KineMed receives an investigator-initiated study grant to further explore mechanism(s) of action associated with Welchol® (colesevelam HCl) in Type 2 Diabetes Mellitus
2008
Time course and dynamics of adipose tissue development in obese and lean Zucker rat pups.
2008
A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes.
View All View All

Pipeline CTA

Translation CTA

Collaboration CTA